相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States
Ashley C. Pariser et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?
Tracy-Ann Moo et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled, phase 3 trial
Viviana Galimberti et al.
LANCET ONCOLOGY (2018)
Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG)
Signe Korsgaard Skriver et al.
ACTA ONCOLOGICA (2018)
Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study
Akiko Chiba et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
Armando E. Giuliano et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial
Harry D. Bear et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
F. Cardoso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
Estrogen Receptor, Progesterone Receptor, and HER2 Status Predict Lymphovascular Invasion and Lymph Node Involvement
Stacy Ugras et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
C. Palmieri et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
Duveken B. Y. Fontein et al.
EUROPEAN JOURNAL OF CANCER (2014)
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
Mila Donker et al.
LANCET ONCOLOGY (2014)
Complete Axillary Lymph Node Dissection Versus Clinical Follow-up in Breast Cancer Patients with Sentinel Node Micrometastasis: Final Results from the Multicenter Clinical Trial AATRM 048/13/2000
Montserrat Sola et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
E. Alba et al.
ANNALS OF ONCOLOGY (2012)
Association of Occult Metastases in Sentinel Lymph Nodes and Bone Marrow With Survival Among Women With Early-Stage Invasive Breast Cancer
Armando E. Giuliano et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Effect of Occult Metastases on Survival in Node-Negative Breast Cancer
Donald L. Weaver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
David N. Krag et al.
LANCET ONCOLOGY (2010)
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
Vladimir F. Semiglazov et al.
CANCER (2007)
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients
Lisa K. Dunnwald et al.
BREAST CANCER RESEARCH (2007)
Pathobiology of preoperative chemotherapy - Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18
ER Fisher et al.
CANCER (2002)
分享论文
